Cargando…
Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization
PURPOSE: To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV). METHODS: In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were f...
Autores principales: | Kamimura, Aya, Miki, Akiko, Kishi, Maya, Okuda, Mina, Hayashida-Hirano, Mayuka, Sakamoto, Mari, Matsumiya, Wataru, Imai, Hisanori, Kusuhara, Sentaro, Nakamura, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153719/ https://www.ncbi.nlm.nih.gov/pubmed/37130134 http://dx.doi.org/10.1371/journal.pone.0284979 |
Ejemplares similares
-
Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy
por: Chubachi-Kamimura, Aya, et al.
Publicado: (2023) -
Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
por: Hayashida, Mayuka, et al.
Publicado: (2020) -
Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity
por: Hayashida, Mayuka, et al.
Publicado: (2020) -
Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity
por: Chubachi, Aya, et al.
Publicado: (2021) -
Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)